Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study

Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D (2005) Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. J Clin Psychiatry 66:294–299 Aguglia E (2000) Reboxetine in the maintenance therapy of depressive disorder in the elderly: a long-term open study. Int J Geriatr Psychiatry 15:784–793 Alamo C, López-Muñoz F, Rubio G, García-García P, Pardo A (2007) Combined treatment with reboxetine in depressed patients with no response to venlafaxine: a 6-week follow-up study. Acta Neuropsychiatr 19:291–296 Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A (2004) Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13(Suppl 1):102–116 Barkley RA (1977) A review of stimulant drug research with hyperactive children. J Child Psychol Psychiatry 18:137–165 Berzewski H, Van Moffaert M, Gagiano CA (1997) Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. Eur Neuropsychopharmacol 7(1):37–47 Biederman J, Spencer T (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234–1242 Biederman J, Gastfriend DR, Jellinek MS (1986) Desipramine in the treatment of children with attention deficit disorder. J Clin Psychopharmacol 6:359–363 Biederman J, Newcorn J, Sprich S (1991) Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 148:564–577 Biederman J, Faraone S, Milberger S, Guite J, Mick E, Chen L, Mennin D, Marrs A, Ouellette C, Moore P, Spencer T, Norman D, Wilens T, Kraus I, Perrin J (1996) A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 53:437–446 Biederman J, Spencer T, Wilens T (2004) Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 7:77–97 Buitelaar JK, Danckaerts M, Gillberg C, Zuddas A, Becker K, Bouvard M, Fagan J, Gadoros J, Harpin V, Hazell P, Johnson M, Lerman-Sagie T, Soutullo CA, Wolanczyk T, Zeiner P, Fouche DS, Krikke-Workel J, Zhang S, Michelson D, Atomoxetine International Study Group (2004) A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 13:249–257 Cantwell DP (1996) Attention deficit disorder: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 35:978–987 Castellanos FX (1997) Toward a pathophysiology of attention-deficit/hyperactivity disorder. Clin Pediatrics (Phil) 36:381–393 Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L (2001) Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 40:307–314 Ding YS, Lin KS, Logan J (2006) PET imaging of norepinephrine transporters. Curr Pharm Design 12:3831–3845 DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998) ADHD Rating Scale-IV: checklists, norms, and clinical interpretation. Guilford, New York Elia J, Borcherding BG, Rapoport JL, Keysor CS (1991) Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 36:141–155 Faraone SV, Sergeant JA, Gillberg C, Biederman J (2003) The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2:104–113 MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for ADHD. Arch Gen Psychiatry 56:1073–1086 Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT, Wong EH (2004) The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drugs Rev 10:23–44 Hansen C, Weiss D, Last CG (1999) ADHD boys in young adulthood: psychosocial adjustment. J Am Acad Child Adolesc Psychiatry 38:165–171 Kasper SF, Resinger E (2001) Efficacy of noradrenergic-selective agents in the treatment of neuropsychiatric diseases. CNS Spectrums 6:710–713 Kasper S, el Giamal N, Hilger E (2000) Reboxetine: the first selective noradrenaline re-uptake inhibitor. Exp Opin Pharmacother 1:771–782 Kratochvil CJ, Vaughan BS, Harrington MJ, Burke WJ (2003) Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Exp Opin Pharmacother 4:1165–1174 López-Muñoz F, Rubio G, Alamo C, García-García P, Pardo A (2006) Reboxetine addition in patients with mirtazapine-resistant depression: a case series. Clin Neuropharmacol 29:192–196 López-Muñoz F, Alamo C, Rubio G, García-García P, Pardo A (2007) Reboxetine combination in treatment-resistant depression to selective serotonin reuptake inhibitors. Pharmacopsychiatry 40:14–19 López-Muñoz F, Alamo C, Quintero-Gutiérrez FJ, García-García P (2008) A bibliometric study of international scientific productivity in attention-deficit hyperactivity disorder covering the period 1980–2005. Eur Child Adolesc Psychiatry 17:381–391 Maidment ID (2003) The use of antidepressants to treat attention deficit hyperactivity disorder in adults. J Psychopharmacol 17:332–336 Mannuzza S, Klein RG (2000) Long-term prognosis in attention-deficit/hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 9:711–726 Massana J, Moller HJ, Burrows GD, Montenegro RM (1999) Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 14:73–80 Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108(5):E83 Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee R, Sangal B, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896–1901 Miller A (1999) Appropriateness of psychostimulant prescription to children: theoretical and empirical perspectives. Can J Psychiatry 44:1017–1024 Mozes T, Meiri G, Ben-Amity G, Sabbagh M, Weizman A (2005) Reboxetine as an optional treatment for hyperkinetic conduct disorder: a prospective open-label trial. J Child Adolesc Psychopharmacol 15:259–269 Otka JE, Mercadante MT, Scahill L, Leckman JF (2001) Reboxetine as a potentially effective treatment for attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 11:203–204 Page ME, Lucki I (2002) Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex. Neuropsychopharmacology 27:237–247 Pliszka SR (2001) New developments in psychopharmacology of attention deficit hyperactivity disorder. Exp Opin Invest Drugs 10:1797–1807 Pliszka SR (2003) Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management. Paediatr Drugs 5:741–750 Pliszka SR, McCracken JT, Maas JW (1996) Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35:264–272 Ratner S, Laor N, Bronstein Y, Weizman A, Toren P (2005) Six-week open-label reboxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 44:428–433 Rubio G, San L, López-Muñoz F, Alamo C (2004) Reboxetine adjunct for partial or nonresponders to antidepressant treatment. J Affect Disord 81:67–72 Servera M, Cardo E (2007) ADHD rating scale-IV en una muestra escolar española: datos normativos y consistencia interna para maestros, padres y madres. Rev Neurol 45:393–399 Simpson D, Plosker GL (2004) Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64:205–222 Spencer T, Wilens T, Biederman J, Faraone SV, Ablon JS, Lapey K (1995) A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434–443 Spencer T, Biederman J, Wilens T, Harding M, O’Donnell D, Griffin S (1996) Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409–432 Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatr 155:693–695 Spencer T, Biederman J, Coffey B, Geller D, Crawford M, Bearman SK, Tarazi R, Faraone SA (2002) A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 59:649–656 Swanson JM, Sergeant JA, Taylor E, Sonuga-Barke EJ, Jensen PS, Cantwell DP (1998) Attention-deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351(9100):429–433 Tanum L (2000) Reboxetine: tolerability and safety profile in patients with major depression. Acta Psychiatr Scand 101(402):37–40 Tehrani-Doost M, Moallemi S, Shahrivar Z (2008) An open-label trial of reboxetine in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 18:179–184 Toren P, Ratner S, Laor N, Lerer-Amisar D, Weizman A (2005) A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: case series. Neuropsychobiology 51:239–242 Toren P, Ratner S, Weizman A, Lask M, Ben-Amitay G, Laor N (2007) Reboxetine maintenance treatment in children with attention-deficit/hyperactivity disorder: a long-term follow-up open study. J Child Adolesc Psychopharmacol 17:803–811 Ulloa RE, Arroyo E, Ávila JM, Cárdenas JA, Cruz E, Gómez D, Higuera F, Rivera FR, Santos G, Velásquez V, Peña F (2005) Algoritmo del tratamiento para el trastorno por déficit de atención con hiperactividad en niños y adolescentes. Salud Ment 28:1–10 Valentini V, Frau R, Di Chiara G (2004) Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J Neurochem 88:917–927 Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R (1999) Reboxetine, a unique selective NRI, prevent relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 60:400–406 Weiss M, Weiss G (2006) Attention deficit hyperactivity disorder. In: Lewis M (ed) Child and adolescent psychiatry. Williams & Williams, Baltimore, pp 645–670 Wender PH, Reimherr FW (1990) Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 147:1018–1020 Wilens T (2006) Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J Clin Psychiatry 67(Suppl 8):32–37 Wilens TE, Spencer TJ (2000) The stimulants revisited. Child Adolesc Psychiatr Clin North Am 9:573–603 Wilens TE, Biederman J, Prince J, Spencer TJ, Faraone SV, Warburton R, Schleifer D, Harding M, Linehan C, Geller D (1996) Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 153:1147–1153 Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, Polisner D, Solhkhah R, Comeau S, Monuteaux MC, Parekh A (2001) A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 158:282–288 Wong EH, Sonders MS, Amara SG, Tinholt PM, Piercey MF, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignori A, Carfagna N, McArthur RA (2000) Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor. Biol Psychiatry 47:818–829 Zhang S, Faries DE, Vowles M, Michelson D (2005) ADHD rating scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Meth Psychiatr Res 14:186–201 Zhou J (2004) Norepinephrine transporter inhibitors and their therapeutic potential. Drugs Future 29:1235–1244